Literature DB >> 34591101

Histologic Findings in Gynecologic Tissue From Transmasculine Individuals Undergoing Gender-Affirming Surgery.

Lawrence Hsu Lin1, Andrea Hernandez2, Alan Marcus1, Fang-Ming Deng1, Esther Adler1.   

Abstract

CONTEXT.—: Gender-affirming surgery is part of a multidisciplinary approach in gender transitioning. Deeper histologic examination may strengthen care for transmasculine individuals and increase the understanding of the influence of hormonal therapy in specific organs. OBJECTIVE.—: To evaluate and catalogue histologic findings of tissue obtained from gender-affirming gynecologic surgery and cervical cytology specimens. DESIGN.—: This is an institutional review board-approved retrospective study that included transmasculine individuals who underwent gender-affirming gynecologic surgery from January 2015 to June 2020. All surgical gynecologic pathology and cervical cytology slides were reviewed by 2 pathologists. RESULTS.—: Fifty-five patients were included, which represented 40 uteri, 35 bilateral ovaries, 15 vaginectomy specimens, and 24 cervical cytology results. The median age was 27 years (range, 18-56), and 94% (50 of 53) of patients were receiving testosterone for at least 1 year. Seventy-five percent (30 of 40) of endometria were inactive, while 25% (10 of 40) showed evidence of cycling. Transitional cell metaplasia was the most common finding in the cervix (17 of 40) and vagina (15 of 15), reflecting a high percentage (4 of 24) of unsatisfactory or ASC-US (atypical squamous cells of undetermined significance) cervical cytologies. Prostatic-type glands were identified in 20% (8 of 40) of cervices and 67% (10 of 15) of vaginectomy specimens. Multiple bilateral cystic follicles and evidence of follicular maturation were present in 57% (20 of 35) of cases. Four cases showed paratubal epididymis-like mesonephric remnant hypertrophy. CONCLUSIONS.—: A comprehensive evaluation of tissue from gender-affirming surgery increases knowledge of the changes following androgen therapy in transmasculine individuals and may contribute to optimal patient care by raising awareness of normal histologic variations in this population.

Entities:  

Mesh:

Year:  2022        PMID: 34591101     DOI: 10.5858/arpa.2021-0199-OA

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  2 in total

1.  Prostatic metaplasia of the vagina in transmasculine individuals.

Authors:  Rena Xu; David A Diamond; Joseph G Borer; Carlos Estrada; Richard Yu; William J Anderson; Sara O Vargas
Journal:  World J Urol       Date:  2022-01-16       Impact factor: 4.226

2.  Cervicovaginal cytology, HPV testing and vaginal flora in transmasculine persons receiving testosterone.

Authors:  Lawrence Hsu Lin; Fang Zhou; Esther Elishaev; Samer Khader; Andrea Hernandez; Alan Marcus; Esther Adler
Journal:  Diagn Cytopathol       Date:  2022-08-08       Impact factor: 1.390

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.